BioSpace News Archive

Prenetics Global Limited, a global leader in genomic and diagnostic testing, announced its unaudited financial results for the first quarter ended March 31, 2022.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced updated safety and durability data from the Phase 1 clinical trial of INB-200 in patients with newly diagnosed glioblastoma multiforme (GBM).

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced participation in the United Mitochondrial Disease Foundation (UMDF) Mitochondrial Medicine 2022 Symposium taking place June 8-11, 2022, in Phoenix, Arizona.

Renalytix announced that KidneyIntelX™ successfully risk-stratified adult patients with type 2 diabetes and early-stage chronic kidney disease for key clinical outcomes, including heart failure hospitalizations and death.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the results of the SUPPORT (Studying the Impact of Patient Treatment Experiences on Patient Hope for Future Major Depressive Disorder Pharmacotherapies).

ASLAN Pharmaceuticals announced that it will host the third and final webinar in its series of Key Opinion Leader events on the emerging atopic dermatitis landscape and eblasakimab on Wednesday, June 22, 2022, at 10:00am ET.

Phase 2 clinical data on the efficacy of D-PLEX 100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation.

Medison Pharma announced today an exclusive multi-regional agreement with argenx to commercialize efgartigimod in 14 countries.

Willow Biosciences Inc. announced today that Willow has incorporated the Onyx Genome Engineering Platform into its strain engineering workflows.